Induction of mutant lymphocytes in cyclophosphamide- and chlorambucil-treated patients

Mutagenesis

Volumn 16, Issue 3, 2001, Pages 197-202

  Sanderson, Barbara J S ^a   Johnson, Kara J ^b   Henner, W David ^b  

^a FLINDERS UNIVERSITY   (Australia)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; TIOGUANINE;

ADULT; ARTICLE; BLOOD; CELL ISOLATION; CELL MUTANT; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE; MULTIPLE SCLEROSIS; MUTAGENIC ACTIVITY; MUTAGENICITY; MUTATION RATE; NONHODGKIN LYMPHOMA; PATIENT MONITORING; PRIORITY JOURNAL;

EID: 0035023502     PISSN: 02678357     EISSN: None     Source Type: Journal    
DOI: 10.1093/mutage/16.3.197     Document Type: Article

References (45)

1. Allegretta, M., Albertini, R.J., Howell, M.D., Smith, L.R., Martin, R., McFarland, H.F., Sriram, S., Brostoff, S. and Steinman, L. (1994) Homologies between T cell receptor junctional sequences unique to multiple sclerosis and T cells mediating experimental allergic encephalomyelitis. J. Clin. Invest., 94, 105-109.
2. Ammenheuser, M.M., Ward, J.B., Jr, Whorton, E.B., Kilian, J.M. and Legator, M.S. (1988) Elevated frequencies of 6-thioguanine resistant lymphocytes in multiple sclerosis patients treated with cyclophosphamide: a prospective study. Mutat. Res., 204, 509-520.
3. Ammenheuser, M.M., Au, W.W., Whorton, E.B., Jr, Belli, J.A. and Ward, J.B., Jr (1991) Comparison of Hprt variant frequencies and chromosome aberration frequencies in lymphocytes from radiotherapy and chemotherapy patients: a prospective study. Environ. Mol. Mutagen., 18, 126-135.
4. - T cell subset contains specialized primed T cells. J. Immunol., 154, 17-25.
5. Benedict, W.F., Baker, M.S., Haroun, L., Choi, E. and Ames, B.N. (1977) Mutagenicity of cancer chemotherapeutic agents in the Salmonella/ microsome test. Cancer Res., 37, 2209-2213.
6. Bochkov, N.P., Filippova, T.V., Kuzin, S.M. and Stukalov, S.V. (1986) Cytogenetic effects of cyclophosphamide on human lymphocytes in vivo and in vitro. Mutat. Res., 159, 103-107.
7. Carter, J.L., Hafler, D.A., Dawson, D.M., Orav, J. and Weiner, H.L. (1988) Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients. Neurology, 38 (Suppl.), 9-14.
8. Chrysostomou, A., Morley, A.A. and Seshadri, R. (1984) Mutation frequency in nurses and pharmacists working with cytotoxic drugs. Aust. NZ J. Med., 14, 831-834.
9. Conen, P.E. and Lansky, G.S. (1961) Chromosome damage during nitrogen mustard therapy. Br. Med. J., ii, 1055-1057.
10. Curtis, R.E., Boice, J.D., Moloney, W.C., Ries, L.G. and Flannery, J.T. (1990) Leukemia following chemotherapy for breast cancer. Cancer Res., 50, 2741-2746.
11. Dawisha, S.M., Gmelig-Meyling, F. and Steinberg, A.D. (1994) Assessment of clinical parameters associated with increased frequency of mutant T cells in patients with systemic lupus erythematosus. Arthrit. Rheum., 37, 270-277.
12. Dempsey, J.L., Seshadri, R. and Morley, A.A. (1985) Increased mutation frequency following treatment with cancer chemotherapy. Cancer Res., 45, 2873-2877.
13. Eder, J.P., Bast, R.C., Peters, W.P., Henner, W.D., Sanchez, E., Schryber, S., Frei, E., III and Schnipper, LE (1986) Prediction of the optimal timing of bone marrow reinfusion after high dose chemotherapy. Cancer Res., 46, 4496-4499.
14. Falck, K., Grohn, P., Sorsa, M., Vainio, H., Heinonen, E. and Holsti, L.R. (1979) Mutagenicity in urine of nurses handling cytostatic drugs. Lancet, 8128, 1250-1251.
15. Gibbs, R.A., Nguyen, P.-N., Edwards, A., Civitello, A.B. and Caskey, C.T. (1990) Multiplex DNA deletion detection and exon sequencing of the hypoxanthine phosphoribosyltransferase gene in Lesch-Nyhan families. Genomics, 7, 235-244.
16. Gibson, J.F., Gompertz, D. and Hedworth-Whitty, R.B. (1984) Mutagenicity of urine from nurses handling cytotoxic drugs. Lancet, 8368, 100-101.
17. Gorelick, N.J., Andrews, J.L., de Boer, J.G., Young, R., Gibson, D.P. and Walker, V.A. (1999) Tissue-specific mutant frequencies and mutational spectra in cyclophosphamide-treated lacI transgenic mice. Environ. Mol. Mutagen., 34, 154-166.
18. Grant, D.D., Glodstein, R., Karsh, J. and Birnboim, H.C. (1999) Elimination of non-viable 6-thioguanine-sensitive T cells from viable T cells prior to PCR analysis. J. Immunol. Methods, 225, 61-66.
19. Grunwald, H.W. and Rosner, F. (1979) Acute leukemia and immunosuppressive drug use. Arch. Intern. Med., 139, 461-466.
20. Huttner, E., Merger, U., Braun, R. and Schoneich, J. (1990) Increased frequency of 6-thioguanine-resistant lymphocytes in peripheral blood of workers employed in cyclophosphamide production. Mutat. Res., 243, 101-107.
21. IARC (1987) Monographs on the Evaluation of Carcinogenic Risks to Humans, Suppl. 7. International Agency for Research on Cancer, Lyon, 440.
22. Jacobson-Kram, D. et al. (1993) Measurement of chromosomal aberration, sister chromatid exchange, hprt mutations, and DNA adducts in peripheral blood lymphocytes of human populations at increased risk for cancer. Environ. Health Perspect., 101 (Suppl. 3), 121-125.
23. Khan, M.A. et al. (1998) p53 mutations in cyclophosphamide-associated bladder cancer. Cancer Epidemiol. Biomarkers Prevent., 7, 397-403.
24. Kaldor, J.M. et al. (1990) Leukemia following chemotherapy for ovarian cancer. New Engl. J. Med., 322, 1-6.
25. Krepinsky, A., Bryant, D.W., Davison, L., Young, B., Heddle, J., McCalla, D.R., Douglas, G. and Michalko, K. (1990) Comparison of three assays for genetic effects of antineoplastic drugs on cancer patients and their nurses. Environ. Mol. Mutagen., 15, 83-92.
26. Lodge, P.A., Allegretta, M., Steinman, L. and Sriram, S (1994) Myelin basic protein peptide specificity and T-cell receptor gene usage of HPRT mutant T-cell clones in patients with multiple sclerosis. Ann. Neurol., 36, 734-740.
27. Morley, A.A., Trainor, K.J., Dempsey, J.L. and Seshadri, R.S. (1985) Methods for study of mutations and mutagenesis in human lymphocytes. Mutat. Res., 147, 363-367.
28. Palmer, R.G., Smith-Burchnell, C.A., Dore, C.J. and Denman, A.M. (1986) Thioguanine-resistant mutations induced by cytotoxic drugs in lymphocytes of patients with connective tissue diseases. Br. J. Rheumatol., 25, 376-379.
29. Palmer, R.G., Smith-Burchnell, C.A., Pelton, B.K., Hylton, W. and Denman, A.M. (1988) Use of T cell cloning to detect in vivo mutations induced by T cell cloning to detect in vivo mutations induced by cyclophosphamide. Arthrit. Rheum., 31, 757-761.
30. Peters, W.P. et al. (1987) Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. Cancer Res., 47, 6402-6406.
31. Povirk, L.F. and Shuker, D.E. (1994) DNA damage and mutagenesis induced by nitrogen mustards. Mutat. Res., 318, 205-226.
32. Sanderson, B.J.S. and Shield, A.J. (1996) Mutagenic damage to mammalian cells by therapeutic alkylating agents. Mutat. Res., 355, 41-57.
33. Sanderson, B.J.S., Johnson, K.J. and Henner, W.D. (1991) Dose-dependent cytotoxic and mutagenic effects of antineoplastic alkylating agents on human lymphoblastoid cells. Environ. Mol. Mutagen., 17, 238-243.
34. Sawada, M., Kubota, M., Lin, Y.W., Watanabe, K., Koishi, S., Usami, I., Akiyama, Y., Matsumura, T. and Furusho, K. (1998) Propspective study of mutant frequencies at the hprt and T-cell receptor gene loci in pediatric cancer patients during chemotherapy. Cancer Epidemiol. Biomarkers Prevent., 7, 711-717.
35. Shulman, L.N. (1993) The biology of alkylating-agent cellular injury. Hematol.-Oncol. Clin. N. Amer., 7, 325-335.
36. Sorsa, M. and Anderson, D. (1996) Monitoring occupational exposure to cytostatic anticancer agents. Mutat. Res., 355, 253-261.
37. Sriram, S. (1994) Longitudinal study of frequency of HPRT mutant T cells in patients with multiple sclerosis. Neurology, 44, 311-315.
38. Staiano, N., Gallelli, J.F., Adamson, R.H. and Thorgiersson, S.S. (1981) Lack of mutagenic activity in urine from hospital pharmacists admixing antitumour drugs. Lancet, 8220, 74-77.
39. Struck, R. and Alberts, D.S. (1984) Blood levels of alkylating metabolites of cyclophosphamide in the mouse after i.v. or oral administration. Cancer Treatment Rep. 68, 765-770.
40. Travis, L.B. et al. (1994) Risk of leukemia following treatment for non-Hodgkin's lymphoma. J. Natl Cancer Inst., 86, 1450-1457.
41. Trotter, J.L., Damico, C.A., Cross, A.H., Pelfrey, C.M., Karr, R.W., Fu, X.T. and McFarland, H.F. (1997) HPRT mutant T-cell lines from multiple sclerosis patients recognize myelin proteolipid protein peptides. J. Neuroimmunol., 75, 95-103.
42. Tucker, M.A., Coleman, C.N., Cox, R.S., Varghese, A. and Rosenberg, S.A. (1988) Risk of second cancer after treatment for Hodgkin's disease. New Engl J. Med., 318, 76-81.
43. Venitt, S., Crofton-Sleigh, C., Hunt, J., Speechley, Y. and Briggs, K. (1984) Monitoring exposure of nursing and pharmacy personnel to cytotoxic drugs: urinary mutation assays and urinary platinum as markers of absorption. Lancet, 8368, 74-77.
44. Walker, V.E., Andrews, J.L., Upton, P.B., Skopek, T.R., de Boer, J.G., Walker, D.M., Shi, X., Sussman, H.E. and Gorelick, N.J. (1999) Detection of cyclophosphamide-induced mutations at the hprt but not the lacI locus in splenic lymphocytes of exposed mice. Environ. Mol. Mutagen.,34, 167-181.
45. Wood, G.M., Dawisha, S. and Gourley, M. (1994) Characteristic of hprt-mutant T cell lines in a lupus patient treated with cyclophosphamide. Arthrit. Rheumat., 37, 1548-1552.